G 2 / M Arrest Sensitises Erythroid Leukemia Cells to TRAIL-induced Apoptosis

  title={G 2 / M Arrest Sensitises Erythroid Leukemia Cells to TRAIL-induced Apoptosis},
  author={S{\'e}verine Cruet-Hennequart and Tanja Paavilainen and Michael O’Dwyer and R{\'e}ka T{\'o}th and Michael P. Carty and Afshin Samali and Eva Szegezdi},
Erythroid leukemia is a heterogeneous disease with very poor prognosis. It may arise de novo, secondary to myelodysplastic syndrome, blast crisis phase of chronic myeloid leukemia, or after cytotoxic therapy of acute myeloid leukemia. The current mainstream treatment of erythroleukemia is cytarabine and anthracyclin-based chemotherapy or bone marrow transplantation. In the current study we found that cytarabine or inhibition of the DNA-damage-activated protein kinase, ATM, induce G2/M arrest… CONTINUE READING


Publications citing this paper.


Publications referenced by this paper.
Showing 1-10 of 33 references

G2 checkpoint abrogators as anticancer drugs.

Molecular cancer therapeutics • 2004
View 5 Excerpts
Highly Influenced

Structural basis for Chk1 inhibition by UCN-01.

The Journal of biological chemistry • 2002
View 5 Excerpts
Highly Influenced

K562--a human erythroleukemic cell line.

International journal of cancer • 1979
View 3 Excerpts
Highly Influenced


G Ortiz-Ferrón, R Yerbes, +3 authors 18 et al. Roscovitine sensitizes breast cancer cells Res
Citation: Hennequart SC, Paavilainen T, O’Dwyer M, Tóth R, Carty M, et al. • 2015
View 1 Excerpt

Similar Papers

Loading similar papers…